Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Shares Outstanding (2019 - 2021)

Historic Shares Outstanding for Lyell Immunopharma (LYEL) over the last 3 years, with Q4 2021 value amounting to $242.7 million.

  • Lyell Immunopharma's Shares Outstanding rose 145901.09% to $242.7 million in Q4 2021 from the same period last year, while for Dec 2021 it was $242.7 million, marking a year-over-year increase of 145901.09%. This contributed to the annual value of $242.7 million for FY2021, which is 145901.09% up from last year.
  • Per Lyell Immunopharma's latest filing, its Shares Outstanding stood at $242.7 million for Q4 2021, which was up 145901.09% from $239.8 million recorded in Q3 2021.
  • Lyell Immunopharma's Shares Outstanding's 5-year high stood at $242.7 million during Q4 2021, with a 5-year trough of $11.2 million in Q4 2019.
  • In the last 3 years, Lyell Immunopharma's Shares Outstanding had a median value of $238.5 million in 2021 and averaged $149.6 million.
  • In the last 5 years, Lyell Immunopharma's Shares Outstanding skyrocketed by 3925.41% in 2020 and then skyrocketed by 145901.09% in 2021.
  • Quarter analysis of 3 years shows Lyell Immunopharma's Shares Outstanding stood at $11.2 million in 2019, then surged by 39.25% to $15.6 million in 2020, then soared by 1459.01% to $242.7 million in 2021.
  • Its last three reported values are $242.7 million in Q4 2021, $239.8 million for Q3 2021, and $238.5 million during Q2 2021.